PATIENT SUPPORT SERVICES

Alongside™ KESIMPTA®
for your patients

80% of commercial patients
get KESIMPTA in 5 days1

Based on prescription and dispense data as of
November 2022.

Services provided by the
Alongside KESIMPTA
Coordinators

Our goal is to make treatment support straightforward. Here's how:

Once you decide, Alongside KESIMPTA delivers.

Your eligible commercial patients get KESIMPTA for $0 out of pocket with the KESIMPTA Access Card.*
They can also get started right away at no cost, no matter their coverage, with our Bridge Program.

Start your patients now.

Download our Start Form or go to CoverMyMeds.com. Patients starting directly through a specialty pharmacy must self-enroll.

Start your patients now.

Download our Start Form or go to CoverMyMeds.com. Patients starting directly through a specialty pharmacy must self-enroll.

DOWNLOAD ENGLISH DOWNLOAD SPANISH

92% of patients with commercial insurance are covered2†

†Based on unrestricted or single-step edit coverage from internal formulary tracker data as of September 2021.

''It only took five days from saying 'yes' to getting KESIMPTA at my door.' - Kristin: mom, real estate agent, KESIMPTA patient.

It only took five days from saying 'yes'
to getting KESIMPTA at my door.

Kristin: mom, real estate agent, KESIMPTA patient.‡

‡Actual KESIMPTA patient who was compensated for their time. Individual results may vary.

We want to make onboarding seamless, so you can focus on your patients.

Your office will be matched with a dedicated Field Reimbursement Manager who will be with you every step of the way, guide you through the prior authorization and appeal process, and help troubleshoot any access or reimbursement issues.

Download our Alongside
KESIMPTA brochure for more
information.

Download our Alongside KESIMPTA brochure for more information.

DOWNLOAD BROCHURE

90% of patients are satisfied with support2§¶

§Alongside KESIMPTA Patient Support Services offers educational and financial resources for up to 2 years, such as supplemental injection training, monthly calls, copay, and insurance support.

Based on a market research survey conducted online from January to September 2021 among 200 RMS patients who recently initiated on KESIMPTA. Participants were asked questions about the Alongside KESIMPTA Patient Program, including the onboarding process, ease of initiation process for KESIMPTA, and support from their coordinators. Participants were asked to rate various features of the Alongside KESIMPTA Patient Program. Respondents were compensated for their participation.

Back to top
'I've had it delivered to my house right on time for each injection... I can't say enough about how easy it is.' - Ananda B: oncology nurse, Kesimpta patient.

I've had it delivered to my house right on time for
each injection.

Ananda: wife, stepmom, oncology nurse, KESIMPTA patient‡

‡Actual KESIMPTA patient who was compensated for their time. Individual results may vary.

‡Actual KESIMPTA patient who was compensated for their time. Individual results may vary.

We're by your patients' side
—for up to 2 years.

The right resources for every type of KESIMPTA patient, including:

Samples, so your patients
can take
their first dose
under your guidance#

Kesimpta sensoready pen icon.

A Sensoready® Training
Pen for
in-office
self-injection training

Supplemental injection
training—via
video chat with
your patient's
Coordinator, or
an in-home visit

Step-by-step videos with
clear, straightforward
instructions.

Step-by-step videos with clear,
straightforward instructions.

WATCH VIDEO

Here are the tools your patients can access anytime.

Here are the tools your patients can
access anytime.

SEE PATIENT RESOURCES

Contact your Sales Representative to order samples and a Sensoready Training Pen.#

Request a Sales Representative
'We offer patients ongoing, personalized support for up to 2 years, not just when they're getting started.' - Leticia, Alongside Coordinator.

We offer patients ongoing, personalized support for up
to 2 years, not just when they're getting started.

Leticia, Alongside Coordinator

Members get tailored support
from a dedicated
Coordinator, so they're
prepared, not overwhelmed.

See what patients like yours are
saying about Alongside KESIMPTA.

See what patients like yours are saying about
Alongside KESIMPTA.

WATCH VIDEO
'My Alongside Kesimpta Coordinator went above and beyond... in the most friendly, compassionate and most knowledgeable way.' - Jennie B: former film crew member, Kesimpta patient.

‡Actual KESIMPTA patient who was compensated for their time. Individual results may vary.

For the full Alongside KESIMPTA
story, download our brochure.

For the full Alongside KESIMPTA story, download
our brochure.

DOWNLOAD BROCHURE

Start patients on KESIMPTA today

DOWNLOAD START FORM

Submit a Start Form by fax or online at CoverMyMeds®

VISIT COVERMYMEDS®
Back to top

MOA=mechanism of action; RMS=relapsing multiple sclerosis.

*Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.

#Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA.

References: 1. Data on file. Program data. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2022. 2. Data on file. Patient market research survey. Novartis Pharmaceuticals Corp; East Hanover, NJ. September 2021.

IMPORTANT SAFETY INFORMATION

Contraindication: KESIMPTA is contraindicated in patients with active hepatitis B virus infection.

WARNINGS AND PRECAUTIONS

Infections: An increased risk of infections has been observed with other anti-CD20 B-cell depleting therapies. KESIMPTA has the potential for an increased risk of infections

INDICATION

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

SEE IMPORTANT SAFETY INFORMATION

INDICATION

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

IMPORTANT SAFETY INFORMATION

Contraindication: KESIMPTA is contraindicated in patients with active hepatitis B virus infection.

WARNINGS AND PRECAUTIONS

Infections: An increased risk of infections has been observed with other anti-CD20 B-cell depleting therapies. KESIMPTA has the potential for an increased risk of infections including serious bacterial, fungal, and new or reactivated viral infections; some have been fatal in patients treated with other anti-CD20 antibodies. The overall rate of infections and serious infections in KESIMPTA-treated patients was similar to teriflunomide-treated patients (51.6% vs 52.7%, and 2.5% vs 1.8%, respectively). The most common infections reported by KESIMPTA-treated patients in relapsing MS (RMS) trials included upper respiratory tract infection (39%) and urinary tract infection (10%). Delay KESIMPTA administration in patients with an active infection until resolved.

Consider the potential increased immunosuppressive effects when initiating KESIMPTA after an immunosuppressive therapy or initiating an immunosuppressive therapy after KESIMPTA.

Hepatitis B Virus: Reactivation: No reports of hepatitis B virus (HBV) reactivation in patients with MS treated with KESIMPTA. However, HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred in patients treated with ofatumumab at higher intravenous doses for chronic lymphocytic leukemia (CLL) than the recommended dose in MS and in patients treated with other anti-CD20 antibodies.

Infection: KESIMPTA is contraindicated in patients with active hepatitis B disease. Fatal infections caused by HBV in patients who have not been previously infected have occurred in patients treated with ofatumumab at higher intravenous doses for CLL than the recommended dose in MS. Perform HBV screening in all patients before initiation of KESIMPTA. Patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], should consult liver disease experts before starting and during KESIMPTA treatment.

Progressive Multifocal Leukoencephalopathy: No cases of progressive multifocal leukoencephalopathy (PML) have been reported for KESIMPTA in RMS clinical studies; however, PML resulting in death has occurred in patients being treated with ofatumumab at higher intravenous doses for CLL than the recommended dose in MS. In addition, JC virus infection resulting in PML has also been observed in patients treated with other anti-CD20 antibodies and other MS therapies. If PML is suspected, withhold KESIMPTA and perform an appropriate diagnostic evaluation. If PML is confirmed, KESIMPTA should be discontinued.

Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to starting KESIMPTA for inactivated vaccines. The safety of immunization with live or live-attenuated vaccines following KESIMPTA therapy has not been studied. Vaccination with live or live-attenuated vaccines is not recommended during treatment and after discontinuation until B-cell repletion.

Vaccination of Infants Born to Mothers Treated with KESIMPTA During Pregnancy. For infants whose mother was treated with KESIMPTA during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines. If the B-cell count has not recovered in the infant, do not administer the vaccine as having depleted B-cells may pose an increased risk in these infants.

Injection-Related Reactions: Injection-related reactions with systemic symptoms occurred most commonly within 24 hours of the first injection, but were also observed with later injections. There were no life-threatening injection reactions in RMS clinical studies.

The first injection of KESIMPTA should be performed under the guidance of an appropriately trained health care professional. If injection-related reactions occur, symptomatic treatment is recommended.

Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections and after discontinuation of therapy until B-cell repletion. Consider discontinuing KESIMPTA therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

Fetal Risk: Based on animal data, KESIMPTA can cause fetal harm due to B-cell lymphopenia and reduce antibody response in offspring exposed to KESIMPTA in utero. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception while receiving KESIMPTA and for at least 6 months after the last dose.

Most common adverse reactions (>10%) are upper respiratory tract infection, headache, injection-related reactions, and local injection-site reactions.

Please see full Prescribing Information, including Medication Guide.

KESIMPTA, the KESIMPTA logo, and SENSOREADY are registered trademarks of Novartis AG.

ALONGSIDE is a trademark of Novartis AG.

CoverMyMeds is a registered trademark of CoverMyMeds, LLC.

All registered trademarks are the property of their respective owners.